Clinical significance and predisposing factors to symptomatic bradycardia and hypotension after percutaneous transluminal coronary angioplasty

Am J Cardiol. 1994 Dec 1;74(11):1085-8. doi: 10.1016/0002-9149(94)90456-1.

Abstract

Of 180 consecutive patients who underwent uneventful percutaneous transluminal coronary angioplasty (PTCA), 25 (13.9%) had at least 1 episode of symptomatic bradycardia and hypotension during the early postprocedure period. Symptomatic bradycardia and hypotension occurred 1 to 10 hours (mean 4 +/- 2) after PTCA. A higher incidence of symptomatic bradycardia and hypotension was found in patients receiving regular treatment with beta blockers (26% vs 10% in patients without beta blockers in their regimen, p < 0.01), diltiazem or verapamil (20% vs 9%, p < 0.025), or both a beta blocker and diltiazem or verapamil (64% vs 11%, p < 0.001). A higher incidence was also associated with angioplasty of the left anterior descending coronary artery compared with angioplasty of the other coronary arteries (22% vs 8%, p < 0.01). It is concluded that symptomatic bradycardia and hypotension is a common occurrence after PTCA. The incidence is higher after PTCA to the left anterior descending coronary artery and in patients receiving diltiazem, verapamil, and beta-blocking agents; it is particularly high in patients receiving a combination of a beta-blocking agent and either diltiazem or verapamil.

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Adult
  • Aged
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Bradycardia / chemically induced
  • Bradycardia / etiology*
  • Coronary Disease / drug therapy
  • Coronary Disease / therapy*
  • Diltiazem / adverse effects
  • Female
  • Humans
  • Hypotension / chemically induced
  • Hypotension / etiology*
  • Incidence
  • Male
  • Middle Aged
  • Risk Factors
  • Verapamil / adverse effects

Substances

  • Adrenergic beta-Antagonists
  • Verapamil
  • Diltiazem